Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 May 6;88(9):1335-8.
doi: 10.1038/sj.bjc.6600914.

Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma

J M Zekri  1 , R E Hough, J M Davies, R Molife, B W Hancock, P C Lorigan
Affiliations
Clinical Trial

Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma

J M Zekri et al. Br J Cancer. .

Abstract

We report the activity and toxicity of docetaxel in 12 evaluable heavily pretreated patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. In all, 42% achieved a partial response, 25% achieved stable disease. Median duration of response was 16 (10-21) weeks. The median overall survival was 70 (9-178) weeks and for responders it was 120 (22-178) weeks. One patient developed one episode of neutropenic sepsis. Docetaxel has limited activity in this group of patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival (n=13).
Figure 2
Figure 2
Survival of diagnoses groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Budman DR, Petroni GR, Johnson JL, Cooper MR, Schlossman DM, Barcos M, Peterson BA (1997) Phase II trial of Docetaxel in non-Hodgkin's lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 15(10): 3275–3279 - PubMed
    1. Crown J (1999) Phase III randomized trials of Docetaxel in patients with metastatic breast cancer. Semin Oncol 26(3, Suppl 8): 33–38 - PubMed
    1. El Helw LM, Lorigan PC, Robinson MH, Coleman RE, Hancock BW (2000) VEDex (vincristine, epirubicin, dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma. Int J Oncol 16: 777–782 - PubMed
    1. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalmen L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of Docetaxel versus Vinorelbine or Ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18(12): 2354–2362. - PubMed
    1. Gandara DR, Edelman MJ, Lau D (1999) Emerging role of Docetaxel (Taxotere) in advanced non-small cell lung cancer. Semin Oncol 26(3, Suppl 10): 3–7 - PubMed